| A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021) (NCT04994522) | Merck Sharp & Dohme LLC | 2022-07-12 |
| A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003) (NCT05386758) | Merck Sharp & Dohme LLC | 2022-06-29 |
| Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543 (NCT05468749) | Concert Pharmaceuticals | 2022-06-06 |
| To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function (NCT05404542) | Cerevel Therapeutics, LLC | 2022-05-10 |
| A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor (NCT05298683) | Hellenic Society of Hematology | 2022-05-01 |
| Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects (NCT05368935) | Genfit | 2022-04-25 |
| A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment (NCT05147493) | Hellenic Society of Hematology | 2022-04-01 |
| Fruquintinib Renal Impairment Study (NCT05216354) | Hutchmed | 2022-03-11 |
| Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants. (NCT05282030) | Sanofi | 2022-03-10 |
| A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment (NCT05200286) | F2G Biotech GmbH | 2022-02-10 |
| A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers (NCT04949438) | AstraZeneca | 2022-01-21 |
| A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People (NCT05117294) | Astellas Pharma Global Development, Inc. | 2021-12-21 |
| Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis (NCT05099445) | Incyte Corporation | 2021-12-14 |
| A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment (NCT05112419) | AstraZeneca | 2021-11-10 |
| Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function (NCT05032235) | Jiangsu HengRui Medicine Co., Ltd. | 2021-11-09 |
| Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment (NCT05086107) | BioVersys AG | 2021-10-08 |
| Bowel Cleansing With Renal Impairment (NCT05349851) | Marco Antonio Alvarez Gonzalez | 2021-10-05 |
| The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics (NCT05004311) | Viatris Innovation GmbH | 2021-09-27 |
| A Study of JNJ-73763989 in Adult Participants With Renal Impairment (NCT04963738) | Janssen Research & Development, LLC | 2021-09-22 |
| A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment (NCT05673603) | Insmed Incorporated | 2021-07-20 |
| Study of ALXN2050 in Participants With Renal Impairment (NCT04623710) | Alexion Pharmaceuticals, Inc. | 2021-07-08 |
| Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function (NCT04810598) | AbbVie | 2021-07-08 |
| Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function. (NCT04909853) | Pfizer | 2021-06-15 |
| A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment (NCT04859439) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-06-15 |
| Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function (NCT04865393) | Spero Therapeutics | 2021-06-08 |
| Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD (NCT04565171) | Sunshine Lake Pharma Co., Ltd. | 2021-04-15 |
| A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants (NCT04616677) | Janssen Research & Development, LLC | 2021-03-31 |
| Surufatinib Renal Impairment Study (NCT04755088) | Hutchison Medipharma Limited | 2021-02-12 |
| Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004) (NCT04678505) | Merck Sharp & Dohme LLC | 2021-02-10 |
| Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment (NCT04646889) | Arthrosi Therapeutics | 2021-01-14 |
| STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT (NCT04616027) | Pfizer | 2021-01-13 |
| PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function (NCT04656795) | Tanabe Pharma America, Inc. | 2020-12-02 |
| A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function (NCT04476849) | Astellas Pharma Global Development, Inc. | 2020-08-10 |
| A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function (NCT04446507) | Zydus Therapeutics Inc. | 2020-07-27 |
| A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants (NCT04426357) | Janssen Pharmaceutica N.V., Belgium | 2020-07-03 |
| Renal Impairment Study of PF-06700841 (NCT04260464) | Pfizer | 2020-07-03 |
| Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment (NCT04469907) | AstraZeneca | 2020-06-22 |
| A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys (NCT04056455) | Millennium Pharmaceuticals, Inc. | 2020-03-04 |
| Kidney Affection in Non Alcaholic Fatty Liver Diseases (NCT04273230) | Assiut University | 2020-03-01 |
| Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function (NCT04249908) | IlDong Pharmaceutical Co Ltd | 2020-02-13 |
| Neuromuscular Blockade in Patients With Severe Renal Impairment (NCT03904550) | University of Texas Southwestern Medical Center | 2019-12-10 |
| Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function (NCT04178447) | Zealand Pharma | 2019-12-10 |
| Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function (NCT04178577) | Spero Therapeutics | 2019-12-06 |
| A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function (NCT05599997) | Bayer | 2019-11-25 |
| Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function (NCT03961932) | ObsEva SA | 2019-05-15 |
| A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease (NCT03913000) | Idorsia Pharmaceuticals Ltd. | 2019-04-29 |
| Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419 (NCT05412472) | Galera Therapeutics, Inc. | 2019-04-04 |
| Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients (NCT03844555) | Genfit | 2019-02-28 |
| Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers (NCT03605277) | Novartis Pharmaceuticals | 2018-11-16 |
| A Renal Impairment Study for PF-04965842 (NCT03660241) | Pfizer | 2018-10-05 |
| PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function (NCT03639610) | Oncopeptides AB | 2018-08-28 |
| Renal Biopsy Unexplained Elevated Serum Creatinine (NCT03586531) | Assiut University | 2018-06-13 |
| Neurotoxic Adverse Effects of Morphine and Oxycodone for Pain in Terminal Patients With Diminished Renal Function (NCT03616639) | Maastricht University Medical Center | 2018-06-04 |
| Glasdegib Renal Impairment Study (NCT03596567) | Pfizer | 2018-05-17 |
| Incidence of HANA Conditions in HIV-infected Individuals (NCT03483584) | Chinese University of Hong Kong | 2018-04-06 |
| Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK) (NCT03436394) | Merck KGaA, Darmstadt, Germany | 2018-03-21 |
| Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients (NCT03506854) | Akcea Therapeutics | 2018-03-20 |
| Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function (NCT03442725) | Ipsen | 2018-02-09 |
| Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment (NCT03443063) | Eisai Inc. | 2018-02-07 |
| Frequency Of Eye Problems In Type 2 Diabetes With Chronic Kidney Disease (NCT03330054) | Mohammed Ramadan Abdallah | 2017-12-01 |
| A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954 (NCT03296787) | Takeda | 2017-11-21 |
| Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex (NCT03284164) | ContraVir Pharmaceuticals, Inc. | 2017-09-28 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects (NCT03235076) | Bayer | 2017-08-15 |
| A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function (NCT03192111) | Syndax Pharmaceuticals | 2017-07-27 |
| A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7) (NCT03159416) | The Medicines Company | 2017-06-22 |
| Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function. (NCT03131479) | Novartis Pharmaceuticals | 2017-04-28 |
| A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901 (NCT02975388) | Hoffmann-La Roche | 2016-12-20 |
| Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment (NCT02852239) | Novartis Pharmaceuticals | 2016-12-19 |
| A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment (NCT02902679) | Bristol-Myers Squibb | 2016-11-01 |
| Single-Dose PK Study of GBT440 in Subjects With Renal Impairment (NCT03161015) | Global Blood Therapeutics | 2016-11-01 |
| Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment (NCT03289208) | Shionogi | 2016-10-27 |
| To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment (NCT02942810) | Wockhardt | 2016-10-25 |
| A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects (NCT02813798) | GlycoMimetics Incorporated | 2016-06-01 |
| Accuracy and Treatment Experience of Two Glucose Monitoring Systems Tested in Patients With Type 1 Diabetes and Renal Impairment (NCT03378271) | Vastra Gotaland Region | 2016-05-05 |
| A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment (NCT02709382) | Wockhardt | 2016-03-01 |
| A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051) (NCT02641067) | Merck Sharp & Dohme LLC | 2016-01-26 |
| A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine (NCT02606084) | Janssen Research & Development, LLC | 2015-12-04 |
| Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment (NCT02578082) | Mylan Inc. | 2015-12-01 |
| Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function (NCT02647918) | Lexicon Pharmaceuticals | 2015-12-01 |
| A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function (NCT02399202) | Novartis Pharmaceuticals | 2015-11-06 |
| Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function (NCT03158792) | Lebanese American University | 2015-10-24 |
| An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis. (NCT02397395) | Janssen R&D Ireland | 2015-05-01 |
| Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function (NCT02442258) | AbbVie | 2015-03-01 |
| Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment (NCT02367872) | Takeda | 2015-03-01 |
| Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001) (NCT02341599) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-12-11 |
| A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics (NCT02286622) | PTC Therapeutics | 2014-12-01 |
| Prematurity as Predictor of Children's Cardiovascular-renal Health (NCT02147457) | Universitaire Ziekenhuizen KU Leuven | 2014-10-01 |
| PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients (NCT02214693) | Dong-A ST Co., Ltd. | 2014-07-01 |
| A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011) (NCT01558674) | Merck Sharp & Dohme LLC | 2014-05-23 |
| Study Of Palbociclib (PD-0332991) In Renal Impairment (NCT02085538) | Pfizer | 2014-05-01 |
| Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects (NCT02007941) | Chong Kun Dang Pharmaceutical | 2014-04-01 |
| Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3) (NCT02058095) | Mayo Clinic | 2014-03-01 |
| Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment. (NCT02048787) | Novartis Pharmaceuticals | 2014-03-01 |
| Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects (NCT02084199) | Lakefront Biotherapeutics NV | 2014-03-01 |
| Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2) (NCT01970176) | Mayo Clinic | 2014-01-09 |
| PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers (NCT02039817) | Conatus Pharmaceuticals Inc. | 2014-01-01 |
| Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment (NCT02508740) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-09-01 |
| Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects (NCT01934166) | H. Lundbeck A/S | 2013-07-01 |
| A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (NCT01904214) | Novartis Pharmaceuticals | 2013-07-01 |
| EVP-6124 Renal Impairment Study (NCT01984723) | FORUM Pharmaceuticals Inc | 2013-06-01 |